| Novartis Pharma Schweiz AG - Exjade 250 mg, dispergierbare Tabletten |
| 57466 | | 02 | | Exjade 250 mg | | dispergierbare Tabletten | | V03AC03 | | Deferasirox | | 03.11.2005 | | |
|
| Composition |
| deferasiroxum 250 mg, crospovidonum, lactosum monohydricum 271.8 mg, cellulosum microcristallinum, povidonum K 30, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.340 mg. |
| Packungsbestandteile |
| Comprimés dispersibles | | | | Principe actif | Concentr. |
|---|
| Déférasirox | 250 mg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Cellulosum Microcristallinum | | | Crospovidonum | | | Lactose Monohydrate | 271.8 mg | | Magnesii Stearas | | | Natrii Laurilsulfas | | | Povidonum K | 30 | | Pro Compresso | | | Silica Colloidalis Anhydrica | |
|
|
|
